by Rajan Dunne, WVC Board Member
I recently spoke at the FDA’s Part 15 public hearing on the “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs” (September 14, 2026), where I recommended that the FDA require psychiatric oversight when psychedelic drugs are used to treat psychiatric illness. One might assume this was already under consideration. Interestingly, the question of psychiatric oversight has been largely absent from the enthusiastic discussions about commercial rollout.
My recommendation comes from years of working in psychedelic clinical trials, both academic and industry-sponsored. There is a great deal of excitement about bringing these treatments into practice, along with considerable investment in the clinics and infrastructure needed to deliver them. There is much to be hopeful about, though the pressures to expand access and build a new industry are not always aligned with the demands of good psychiatric care.
Administering a drug is not the same as treating an illness. Good psychiatric care requires an understanding of the illness, its natural course, the range of treatment options, and responsibility for the patient over time. Sometimes the appearance of treatment can be mistaken for the thing itself. We should be honest with patients about what we are offering, and what expertise stands behind it. A Trojan horse is not a container of integrity.
There is also the question of how psychiatric treatment fits into the much longer history of psychedelic use. Spiritual, ceremonial, personal, and other uses have their own traditions and purposes, quite apart from psychiatry. If “psychiatric treatment” becomes the only sanctioned pathway, we create incentives to call things psychiatric or medical that aren’t. This risks weakening the integrity of psychiatric care, with potentially serious consequences for patients who have placed their trust in it. It also places other forms of psychedelic use under a framework that is inappropriate for them.
I sincerely hope psychiatry is never put in charge of all psychedelic use. That would be well beyond its rightful scope. But when we’re talking about treating psychiatric illness, as we were at the FDA, psychiatric oversight is appropriate. Its absence from the regulatory discussion deserves consideration.
